The screening pathway varies slightly depending on if the hospital trust is in a high or low prevalence area for sickle cell and thalassaemia.
Healthcare professionals can use the high and low prevalence trusts document to see which pathway to use.
The Family Origin Questionnaire (FOQ) assesses the likelihood of a person being a genetic carrier by looking at their ancestry and family origins. The form includes guidance for use in both high and low prevalence areas.
Within this framework, there are a number of specific activities that relate to SCT screening.
The standards for SCT screening document explains how to provide linked antenatal and newborn screening for sickle cell and thalassaemia. It also sets out the required standards to achieve and how they are monitored.
There are national guidelines for reporting and managing incidents in NHS population screening.
Key performance indicators
There is a process across screening for setting and measuring Key Performance Indicators.
Each screening programme has specified failsafe mechanisms, to help identify people who are not screened, or whose samples are not processed correctly. These back-up mechanisms support routine screening.
If something goes wrong, the failsafe will identify the problem and specify an action to put it right and ensure a safe outcome.
The newborn outcomes project tracks babies identified with a haemoglobin condition into care services, to evaluate the linked antenatal and newborn screening programme.
All screening providers need to record data about their activity. The national quality assurance programme provides guidance on the data to provide and ways to provide it.
Screening laboratories collect data to meet the set screening standards and use the data collection templates to submit the information to the screening programme.
Two forms are available for data collection for antenatal screening, to reflect different care pathways in high and low prevalence areas. Use the list of trusts and their prevalence to see the correct form to use.
The newborn laboratory data form is for collecting data from newborn blood spot screening.
Annual data reports
The annual data report evaluates the performance of screening each year. This document sets out the performance of:
Added Sickle cell and thalassaemia screening: newborn outcomes system document.
Added link in antenatal screening section to guidance on contacting fathers for screening.
Added 'Sickle cell and thalassaemia screening: outcome data', 'Sickle cell and thalassaemia screening: outcome data collection template' and removed 'Newborn outcomes project: definition and implementation'
and 'Newborn outcomes project: data collection templates'.
Replaced out of date antenatal failsafe document with new guidance on checks and audits.
Added of new amniocentesis and CVS diagnostic test leaflet to collection.